Molbio’s digital radiology arm secures CE MDR certification for its medical imaging portfolio

Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance

Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027

As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million

FDA okays Eli Lilly’s new weight-loss pill, expanding options for millions

The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants

Bayer plans to offer Eylea 2mg at lower cost in India for benefit of retinal disease patients

Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina

Lupin completes acquisition of VISUfarma

The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe

Agilent opens new customer experience center in Mumbai

The center brings together hands on technology demonstrations, application expertise, and commercial operations

Orca Bio’s Orca-T FDA review extended to July 2026

Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push

The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio

Biogen bags FDA nod for high dose SPINRAZA in spinal muscular atrophy

The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases

Torqur taps Lonza to power late-stage push for skin cancer therapy

Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds